Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Share-based Compensation: 2017-2024

Historic Share-based Compensation for Solid Biosciences (SLDB) over the last 8 years, with Dec 2024 value amounting to $3.8 million.

  • Solid Biosciences' Share-based Compensation rose 97.16% to $3.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $10.5 million, marking a year-over-year increase of 37.95%. This contributed to the annual value of $10.5 million for FY2024, which is 37.95% up from last year.
  • Per Solid Biosciences' latest filing, its Share-based Compensation stood at $3.8 million for Q4 2024, which was up 27.58% from $3.0 million recorded in Q3 2024.
  • Solid Biosciences' 5-year Share-based Compensation high stood at $3.8 million for Q4 2024, and its period low was $1.5 million during Q3 2022.
  • For the 3-year period, Solid Biosciences' Share-based Compensation averaged around $2.1 million, with its median value being $1.9 million (2023).
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 55.39% in 2022, then skyrocketed by 97.16% in 2024.
  • Quarterly analysis of 5 years shows Solid Biosciences' Share-based Compensation stood at $2.5 million in 2020, then surged by 35.62% to $3.4 million in 2021, then tumbled by 53.53% to $1.6 million in 2022, then climbed by 22.12% to $1.9 million in 2023, then soared by 97.16% to $3.8 million in 2024.
  • Its Share-based Compensation was $3.8 million in Q4 2024, compared to $3.0 million in Q3 2024 and $2.1 million in Q2 2024.